Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ReRAD: A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma

NCT03126266 is registered in ClinicalTrials.gov with University of Calgary as lead sponsor.

NCT NCT03126266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03126266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ReRAD: A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma
Lead sponsor
University of Calgary
Phase
Not applicable
Overall status
Completed
Start date
April 15, 2017
Completion date
November 25, 2024
Enrollment
27 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or progressive diffuse intrinsic pontine glioma